Clinical Trials


Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

This study has been completed
ViiV Healthcare

Information provided by (Responsible Party)
ViiV Healthcare Identifier

First received: May 31, 2002
Last updated: April 6, 2015
Last Verified: October 2010
History of Changes


This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.

Condition Intervention Phase
HIV Infection

Drug : abacavir/lamivudine/zidovudine
Drug : tenofovir
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase IV, Open-label, Multicenter Study of Treatment With TRIZIVIR (Abacavir 300mg/Lamivudine 150mg/Zidovudine 300mg) Twice Daily and Tenofovir 300mg Once-daily for 48 Weeks in HIV-infected Subjects Experiencing Early Virologic Failure (ZIAGEN Intensification Protocol)

Further study details as provided by ViiV Healthcare:

Primary Outcome Measures

  • HIV viral load response at 48 weeks as measured by proportion of subjects with undetectable viral load. [ Time Frame: 48 weeks ]
Secondary Outcome Measures:
  • Safety Viral load response at 24 weeks Change in T-cell count Resistance Health outcomes [ Time Frame: 24 weeks ]

Enrollment: 100
Study Start Date: March 2002
Study Completion Date: August 2004
Primary Completion Date: August 2004 (Final data collection date for primary outcome measure)



Ages Eligible for Study: 18 Years and older  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  


Inclusion Criteria:

  • Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) -boosted or unboosted- or NNRTI (non-nucleoside reverse transcriptase inhibitor).
  • Plasma HIV - 1 RNA was <400 copies/ml on at least 2 documented occasions prior to viral rebound.
  • Have a plasma HIV - 1 RNA value >400 copies/ml and <10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks.
  • A CD4+ lymphocyte count less than or equal to 100.

Exclusion Criteria:
  • Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously.
  • Have not had an AIDS defining illness within 30 days of screen.
  • Pregnant or breast-feeding.
  • Specified viral genotypes upon screening.
  • And other inclusion or exclusion criteria to be evaluated by the physician.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00038506


United States, California
GSK Investigational Site
Los Angeles, California, United States, 90027
GSK Investigational Site
San Rafael, California, United States, 94903
United States, Florida
GSK Investigational Site
Fort Lauderdale, Florida, United States, 33145
GSK Investigational Site
Jacksonville, Florida, United States, 32206
GSK Investigational Site
Lake Worth, Florida, United States, 33463
GSK Investigational Site
Miami Beach, Florida, United States, 33139
GSK Investigational Site
Miami, Florida, United States, 33136
GSK Investigational Site
North Miami, Florida, United States, 33161
GSK Investigational Site
Orlando, Florida, United States, 32804
GSK Investigational Site
Tallahassee, Florida, United States, 32303
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30309
GSK Investigational Site
Decatur, Georgia, United States, 30033
United States, Illinois
GSK Investigational Site
Chicago, Illinois, United States, 60657
GSK Investigational Site
Maywood, Illinois, United States, 60153
United States, Indiana
GSK Investigational Site
Lafayette, Indiana, United States, 47904
United States, Michigan
GSK Investigational Site
Berkeley, Michigan, United States, 48072
United States, New York
GSK Investigational Site
Bronx, New York, United States, 10461
GSK Investigational Site
New York, New York, United States, 10014
GSK Investigational Site
Valhalla, New York, United States, 10595
United States, Oklahoma
GSK Investigational Site
Tulsa, Oklahoma, United States, 74114
United States, Texas
GSK Investigational Site
Arlington, Texas, United States, 76015
GSK Investigational Site
Dallas, Texas, United States, 75208
GSK Investigational Site
Dallas, Texas, United States, 75216
GSK Investigational Site
Dallas, Texas, United States, 75246
GSK Investigational Site
Houston, Texas, United States, 77004
United States, Washington
GSK Investigational Site
Seattle, Washington, United States, 98104
United States, Wisconsin
GSK Investigational Site
Green Bay, Wisconsin, United States, 54301

Sponsors and Collaborators

ViiV Healthcare


Study Director: GSK Clinical Trials, MD GlaxoSmithKline
More Information

More Information

Responsible Party: Study Director, GSK Identifier: NCT00038506   History of Changes  
Other Study ID Numbers: ESS 30005  
Study First Received: May 31, 2002  
Last Updated: April 6, 2015  

Keywords provided by ViiV Healthcare:

HIV-1 TRIZIVIR Tenofovir

Additional relevant MeSH terms:
HIV Infections
Lamivudine, zidovudine drug combination processed this data on July 08, 2020
This information is provided by